Detalles de la búsqueda
1.
The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
Pediatr Transplant
; 28(1): e14471, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37294621
2.
The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: IV-consensus guidelines for the management of post-transplant lymphoproliferative disorders in children and adolescents.
Pediatr Transplant
; 28(5): e14781, 2024 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38808744
3.
The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: II-consensus guidelines for prevention.
Pediatr Transplant
; : e14350, 2022 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36369745
4.
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Ann Hematol
; 100(8): 2043-2050, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973053
5.
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.
Int J Gynecol Cancer
; 31(9): 1199-1206, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407962
6.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868632
7.
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
Haematologica
; 108(10): 2814-2819, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36891749
8.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Blood
; 125(7): 1091-7, 2015 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25525118
9.
Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events.
Int J Gynecol Cancer
; 32(12): 1621-1622, 2022 12 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191955
10.
Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study.
Blood Cells Mol Dis
; 62: 24-31, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27838551
11.
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Ann Hematol
; 93(12): 1953-63, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25307456
12.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia
; 38(6): 1307-1314, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38678093
13.
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Lancet Oncol
; 13(2): 196-206, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22173060
14.
Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.
Adv Ther
; 40(3): 1267-1281, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36681739
15.
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
J Clin Invest
; 133(12)2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37159273
16.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Hemasphere
; 7(7): e904, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427146
17.
Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Cancer
; 118(19): 4715-24, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22392525
18.
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Leukemia
; 36(10): 2468-2478, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35974101
19.
Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
Front Immunol
; 13: 994552, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36304469
20.
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.
Haematologica
; 96(7): 1067-71, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21719885